S&P 500 Futures Decline In Premarket Trading; Paramount Global, Revolution Medicines Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Paramount Global Cl B (PARA) was up 9.6% in pre-mar
Dow JonesApr 19 07:31 ET
Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Revolution Medicines (RVMD)
TipRanksApr 19 07:30 ET
Express News | Revolution Medicines Inc : Stifel Raises Target Price to $43 From $34: Stifel Raises Target Price to $43 From $34
Moomoo 24/7Apr 19 06:49 ET
Revolution Medicines(RVMD.US) Officer Sells US$619.47K in Common Stock
$Revolution Medicines(RVMD.US)$ Officer GOLDSMITH MARK A sold 17,500 shares of common stock on Apr 10, 2024 at an average price of $35.3981 for a total value of $619.47K.Source: Announcement What is s
moomoo NewsApr 12 20:51 ET
Revolution Medicines(RVMD.US) Director Sells US$79,735 in Common Stock
$Revolution Medicines(RVMD.US)$ Director Patel Sushil sold 2,155 shares of common stock on Apr 10, 2024 at an average price of $37 for a total value of $79,735.Source: Announcement What is statement o
moomoo NewsApr 12 17:06 ET
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Seeking AlphaApr 12 11:34 ET
Express News | Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $45 From $43
Moomoo 24/7Apr 12 08:52 ET
Top 3 Health Care Stocks That May Collapse In Q2
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indica
BenzingaApr 12 08:34 ET
Revolution Medicines Price Target Raised to $45.00/Share From $43.00 by Oppenheimer
Revolution Medicines Price Target Raised to $45.00/Share From $43.00 by Oppenheimer
Dow JonesApr 12 08:23 ET
Oppenheimer Sticks to Their Buy Rating for Revolution Medicines (RVMD)
TipRanksApr 12 07:47 ET
Revolution Medicines Receives Buy Rating Amid Promising Cancer Treatment Data and Expanded Market Opportunities
TipRanksApr 12 06:26 ET
Revolution Medicines Is Maintained at Buy by Needham
Revolution Medicines Is Maintained at Buy by Needham
Dow JonesApr 12 06:25 ET
Express News | Needham Maintains Buy on Revolution Medicines, Raises Price Target to $46
Moomoo 24/7Apr 12 06:15 ET
Express News | Revolution Medicines Inc : Oppenheimer Raises Target Price to $45 From $43
Moomoo 24/7Apr 12 00:18 ET
Top Gap Ups and Downs on Wednesday: BABA, PLD, UBS and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 10 20:47 ET
Form 144 | Revolution Medicines(RVMD.US) Director Proposes to Sell 164.95K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 10, $Revolution Medicines(RVMD.US)$、$REVOLUTION MEDICINES INC C/WTS (TO PUR COM)(RVMDW.US)$ Director REBECCA EVE GOLDSMITH TRU/A DTD 12/15/2011 intends to sell 5,000 shares
moomoo NewsApr 10 16:24 ET
Form 144 | Revolution Medicines(RVMD.US) Director Proposes to Sell 247.43K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 10, $Revolution Medicines(RVMD.US)$、$REVOLUTION MEDICINES INC C/WTS (TO PUR COM)(RVMDW.US)$ Director MARK A GOLDSMITH TODSUBJECT TO STA RULES intends to sell 7,500 shares o
moomoo NewsApr 10 16:24 ET
Revolution Medicines Gains 10%+ on Word of Experimental Anti-Tumor Drug
Revolution Medicines rose more than 10% Wednesday after the biotech firm reported the discovery and preclinical-to-clinical translation for its anti-tumor drug RMC-6236.
Jerry KronenbergApr 10 16:11 ET
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ascent Solar Technologies, Inc. (NASDAQ:ASTI) fell sharply during Wednesday's session after the company announced pricing of a $6 million public offering of shares at $0.14 per share. Ascen
BenzingaApr 10 14:07 ET
Revolution Medicines Raised to Strong Buy From Outperform by Raymond James
Revolution Medicines Raised to Strong Buy From Outperform by Raymond James
Dow JonesApr 10 13:27 ET
No Data
No Data